BOSENTAN - AN OVERVIEW

six The phosphodiesterase-5 inhibitor sildenafil is accredited for PAH in FC I–IV from the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies certified to be used in PAH. As no oral agent has proven superiority there stays debate concerning which re